Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Cleared to Start China Trials of PIKA-based Cancer Immunotherapy

publication date: Jun 27, 2019

Yisheng Biopharma of Beijing was cleared to start China trials of its PIKA-based immunotherapy to treat solid tumors. YS-ON-001 is a first-in-class immunomodulating product designed to promote both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. The US FDA has granted US Orphan Drug Designation to YS-ON-001 for pancreatic cancer and hepatocellular carcinoma. The PIKA technology is already being tested in two other Yisheng candidates: vaccines for hepatitis B and rabies. Currently in a China Phase III trial, the rabies vaccine is Yisheng's lead product. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital